沙利度胺在急性白血病患者中的应用研究

Application of Thalidomide in Patients with Acute Leukemia

目的探讨沙利度胺在急性白血病患者中的应用效果。方法研究对象方便选取于2015年6月—2020年5月该院收治的急性白血病患者,共计75例。75例急性白血病患者以随机数表法进行分组。对照组37例接受常规化疗治疗,研究组38例在此基础上应用沙利度胺治疗。根据《血液病诊断及疗效标准》第4版中的内容对于两组临床疗效进行评价,对比两组治疗前后血管内皮生长因子(VEGF)与成纤维细胞生长因子(bFGF)水平,以及治疗期间的不良反应情况(包括恶心呕吐、肝肾功能损伤、感染,以及血红蛋白降低、血小板减少、白细胞减少等血液系统不良反应)。结果在两组急性白血病患者总有效率对比中,研究组(86.84%)较对照组(62.16%)更高,差异有统计学意义(χ^(2)=6.037,P<0.05)。治疗后研究组VEGF(207.65±52.60)pg/mL、bFGF(2.05±0.30)ng/mL较对照组(295.62±55.48)pg/mL、bFGF(2.29±0.32)ng/mL更低,差异有统计学意义(t=7.048、3.352,P<0.01)。在急性白血病患者的不良反应情况对比中,研究组恶心呕吐、肝肾功能损伤、感染、血液系统不良反应分别为5.26%、2.63%、5.26%、2.63%与对照组的5.41%、8.11%、5.41%、8.11%比较,差异无统计学意义(χ^(2)=0.237、0.293、0.237、0.293,P>0.05)。结论沙利度胺在急性白血病患者中具有显著的应用效果,可以有效调节VEGF与bFGF表达,抑制血管新生。

Objective To investigate the effect of thalidomide in patients with acute leukemia.Methods The study subjects were convenient selected 75 patients with acute leukemia admitted to the hospital from June 2015 to May 2020.75 patients with acute leukemia were grouped by random number table method.37 cases in the control group received conventional chemotherapy,and 38 cases in the study group were treated with thalidomide on this basis.The clinical efficacy of the two groups was evaluated according to the contents of the 4th edition of the"Criteria for Diagnosis and Efficacy of Hematological Diseases".The levels of vascular endothelial growth factor(VEGF)and fibroblast growth factor(bFGF)before and after treatment were compared between the two groups,as well as adverse reactions(including:nausea and vomiting,liver and kidney damage,infection,and blood system adverse reactions such as hemoglobin reduction,thrombocytopenia,and leukopenia)during treatment.Results In the comparison of the total effective rate of the two groups of acute leukemia patients,the study group(86.84%)was higher than the control group(62.16%),and the difference was statistically significant(χ^(2)=6.037,P<0.05).After treatment,VEGF(207.65±52.60)pg/mL and bFGF(2.05±0.30)ng/mL in the study group were lower than those in the control group(295.62±55.48)pg/mL and bFGF(2.29±0.32)ng/mL,and the difference was statistically significant(t=7.048,3.352,P<0.01).In the comparison of the adverse reactions of patients with acute leukemia,the study group's nausea and vomiting,liver and kidney damage,infection,and blood system adverse reactions were 5.26%,2.63%,5.26%,2.63%,compared with the control group 5.41%,8.11%,5.41%,8.11%,there was no statistically significant difference(χ^(2)=0.237,0.293,0.237,0.293,P>0.05).Conclusion Thalidomide has a significant application effect in patients with acute leukemia.It can effectively regulate the expression of VEGF and bFGF,inhibit angiogenesis.